Excessive immune stimulation leading to adverse autoimmune events has previously been reported following anti–CTLA-4 treatment in melanoma patients (7), and therefore it is possible that the optimal therapeutic dose may vary between applications. This evidence concerns the gene CTLA4 and melanoma.